Mohammed Al-Amoodi
Interventional Cardiology · Montgomery, OHNPI 1083866149
Payments from drug & device makers
Across 141 payments — averaging $224.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Edwards Lifesciences$4K
- Abbott$3K
- Abiomed$1K
- Boston Scientific$413
- Astellas Pharma US Inc$197
- plus $1K from 25 others
What the payments were for
- Grants$21,00066%
- Travel & lodging$4,40914%
- Food & beverage$5,71218%
- Education$5542%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 13 | $21,478 |
| Edwards Lifesciences | 47 | $4,184 |
| Abbott | 28 | $2,902 |
| Abiomed | 4 | $1,215 |
| Boston Scientific | 5 | $413 |
| Astellas Pharma US Inc | 3 | $197 |
| Kestra Medical Technology Services, Inc. | 1 | $146 |
| Inari Medical, Inc. | 2 | $135 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Spineology Inc. | 1 | $119 |
| Philips North America LLC | 1 | $104 |
| Johnson & Johnson | 6 | $96 |
| W. L. Gore & Associates, Inc. | 2 | $61 |
| Novartis | 3 | $44 |
| Merck | 2 | $39 |
| Shockwave Medical, Inc | 1 | $38 |
| Livanova USA, Inc. | 2 | $36 |
| Biosense Webster, Inc. | 1 | $35 |
| Boehringer Ingelheim | 2 | $35 |
| Amgen | 2 | $34 |
| Impulse Dynamics (USA) Inc. | 1 | $33 |
| Bayer | 2 | $33 |
| Pfizer | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Terumo Medical Corporation | 1 | $25 |
| Angiodynamics, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,215
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,060
- MitraClip$905
- SUPERA$516
- PASCAL$465
- MitraClip System$381
- Ensite Cardiac Mapping System$374
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$151
- AVVIGO Guidance System$150
- Assure WCD$146
- MAMBA$130
- UPTRAVI$125
- OPSUMIT$125
- OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM$119
- FLOWTRIEVER CATHETER, S$109
- CT THROMBECTOMY SYSTEM KIT$109
- US Und$104
How this compares
$31,675 in reported general payments places this provider in the 70th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 117 | $83,723 |
| FarxigaDapagliflozin Propanediol | 76 | $59,638 |
| JardianceEmpagliflozin | 69 | $56,972 |
| EntrestoSacubitril/Valsartan | 20 | $22,436 |
| XareltoRivaroxaban | 13 | $7,236 |
| Ezetimibe | 212 | $4,773 |
| Colchicine | 18 | $3,770 |
| ClopidogrelClopidogrel Bisulfate | 136 | $1,205 |
| Rosuvastatin Calcium | 86 | $1,073 |
| Atorvastatin Calcium | 48 | $279 |
| Nifedipine ErNifedipine | 13 | $241 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 39 | $194 |
| Spironolactone | 46 | $187 |
| Nitroglycerin | 15 | $181 |
| Carvedilol | 33 | $180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27 | $83,723117 claims |
| AstraZenecaFarxiga | $14 | $59,63876 claims |
| Boehringer IngelheimJardiance | $35 | $56,97269 claims |
| NovartisEntresto | $44 | $22,43620 claims |
| Johnson & JohnsonXarelto | $96 | $7,23613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Montgomery
- Santiago GarciaCincinnati$3.6M
- Gary AnselColumbus$3.4M
- Dean KereiakesCincinnati$3.4M
- Steven YakubovColumbus$3.2M
- Joseph ChooCincinnati$1.9M
- Carlos Sanchez SotoColumbus$1.7M
- John CheathamColumbus$1.7M
- Brendan DuffyCanton$1.5M
- Timothy HenryCincinnati$1.3M
- Gary FishbeinCenterville$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.